Skip to main content
Premium Trial:

Request an Annual Quote

Rebecca Galler Robison, Stephan Herrera, Robert Schaub, Page Bouchard

Premium
Rebecca Galler Robison, senior director of corporate strategy for Sirna Therapeutics, has left the RNAi drug developer. Assuming her duties is Stephan Herrera, who has become Sirna’s executive director of investor relations.
 
According to Herrera, Robison’s departure was linked to Sirna’s ongoing relocation of employees from its former headquarters on Boulder, Colo., to its new headquarters in San Francisco.
 

 
Aptamer drug development firm Archemix said this week that it has appointed Robert Schaub as vice president of preclinical discovery.
 
Schaub, who was most recently assistant vice president for cardiovascular and metabolic diseases at Wyeth, holds a bachelor's degree in biology from the University of Nevada and a PhD from Washington State University, the company said.
 

Archemix also announced that Page Bouchard, senior vice president at the company, will head the research and preclinical development group. Bouchard joined Archemix in 2004 as senior vice president of preclinical drug discovery and preclinical development.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.